answer text |
<p>We work with the Department of Health and Social Care (DHSC), Department for International
Development, and UK Research and Innovation (UKRI) to support research on platform
vaccine technologies and diagnostic tools that can be utilised as a rapid response
during a pandemic. These form a component of the current DHSC and UKRI COVID-19 rapid-response
call for proposals to address the threat of this novel coronavirus. Platform vaccines
and diagnostics are an integral part of UKRI’s current approach for the development
and translation of research findings into tangible benefits, with research funded
across UKRI councils</p><p> </p><p>DHSC and UKRI lead the UK Vaccine Network which
brings together funders, industry and academia to identify and target investment opportunities
for the most promising vaccines and vaccine technologies, including platform vaccine
and diagnostic tools to combat infectious diseases with epidemic potential and to
address structural issues related to the UK’s vaccine infrastructure.</p><p> </p><p>Through
the Network two vaccine manufacturing hubs have been established to streamline vaccine
manufacturing. A £10 million award to Professor Robin Shuttock at Imperial College
London aims to revolutionise the vaccine manufacture, stabilisation and storage, reducing
costs, increasing efficiency and improving prevention of existing and new diseases.
A £7 million award to Professor Tarit Mukhopadhyay at University College London aims
to establish the UK as a global centre for vaccine discovery, development and manufacture,
while also ensuring that new vaccine manufacturing processes can be used in low and
middle income countries.</p>
|
|